title: [Cervical carcinoma staging with magnetic resonance tomography: the use of gadolinium-DOTA with 31 patients].
abstract: Thirty-one patients with histologically proven carcinoma of the cervix were studied by contrast-enhanced MRI. T2-weighted sequences in a spin-echo mode and T1-weighted sequences were carried out before and after the application of Gd-DOTA. This resulted in improved staging. Contrast-enhanced MRI provided valuable additional information concerning tumour extension into the parametrium. In the presence of motion artifacts and ill-defined infiltration into the parametrium on the T2 sequences, the use of contrast-enhanced T1 images provided a valuable addition to the investigation of carcinoma of the cervix.
authors.affiliation: Röntgendiagnostisches Zentralinstitut, Departement für Medizinische Radiologie, Universitätsspital, Zürich.
authors.forename: S
authors.initials: S
authors.lastname: Thurnher
authors.forename: M
authors.initials: M
authors.lastname: McPhillips
authors.forename: G K
authors.initials: GK
authors.lastname: von Schulthess
authors.forename: B
authors.initials: B
authors.lastname: Marincek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D003287:Contrast Media; D005069:Evaluation Studies as Topic; D005260:Female; D005682:Gadolinium; D006571:Heterocyclic Compounds; D006801:Humans; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging / Q000295:instrumentation / Q000379:methods*; D008875:Middle Aged; D009367:Neoplasm Staging; D009942:Organometallic Compounds; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery
chemical_list: D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D005682:Gadolinium
vernacular_title: Staging des Zervixkarzinoms mit der magnetischen Resonanztomographie: Anwendung von Gadolinium-DOTA bei 31 Patientinnen.